Identification of novel small-molecule compounds that inhibit the proproliferative Krüppel-like factor 5 in colorectal cancer cells by high-throughput screening

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 563-570

  Bialkowska, Agnieszka B ^a   Du, Yuhong ^a   Fu, Haian ^a   Yang, Vincent W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 METHYL 5 ISOTHIAZOLYL)UREA; 1 PHENYL 3 (2 THIAZOLYL)THIOUREA; 2 CHLORO 5 NITROBENZANILIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; ANTINEOPLASTIC AGENT; DEQUALINIUM; DIHYDROOUABAIN; EMETINE; KRUPPEL LIKE FACTOR 5; LUCIFERASE; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; NSC 95397; OUABAIN; PHORBOL 13 ACETATE 12 MYRISTATE; PICEATANNOL; SEROTONIN ANTAGONIST; TYRPHOSTIN; TYRPHOSTIN AG879; UNCLASSIFIED DRUG; WORTMANNIN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; START CODON; BIOLOGICAL MODEL; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL TUMOR; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; PATHOLOGY; PHYSIOLOGY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HCT116 CELLS; HT29 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MODELS, BIOLOGICAL; SMALL MOLECULE LIBRARIES; TRANSFECTION;

EID: 66449086248     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0767     Document Type: Article

References (41)

1. de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and colorectal cancer. Front Biosci 2007;12:471-491 (Pubitemid 46852800)
2. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005;19:877-890 (Pubitemid 40548056)
3. Jass JR. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006;12:273-287 (Pubitemid 46524134)
4. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850 (Pubitemid 40558990)
5. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007;13:3784-3791 (Pubitemid 47272303)
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767 (Pubitemid 20185636)
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170 (Pubitemid 26358996)
8. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113 (Pubitemid 350134889)
9. Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 2000;32:1103-1121 (Pubitemid 32008299)
10. Ghaleb AM, Yang VW. The pathobiology of Kruppel-like factors in colorectal cancer. Curr Colorectal Cancer Rep 2008;4:59-64.
11. McConnell BB, Ghaleb AM, Nandan MO, Yang VW. The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 2007;29:549-557 (Pubitemid 46903942)
12. Sun R, Chen X, Yang VW. Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem 2001;276:6897-6900 (Pubitemid 37391980)
13. Chanchevalap S, Nandan MO, Merlin D, Yang VW. All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5. FEBS Lett 2004;578:99-105. (Pubitemid 39576108)
14. Kawai-Kowase K, Kurabayashi M, Hoshino Y, Ohyama Y, Nagai R. Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells. Circ Res 1999;85:787-795 (Pubitemid 29504153)
15. Nandan MO, Chanchevalap S, Dalton WB, Yang VW. Kruppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation. FEBS Lett 2005;579:4757-4762 (Pubitemid 41218659)
16. Nandan MO, Yoon HS, Zhao W, et al. Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene 2004;23:3404-3413 (Pubitemid 38669830)
17. Nandan MO, McConnell BB, Ghaleb AM, et al. Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology 2008;134:120-130 (Pubitemid 350309321)
18. McConnell BB, Klapproth JM, Sasaki M, Nandan MO, Yang VW. Kruppel-like factor 5 mediates transmissible murine colonic hyperplasia caused by Citrobacter rodentium infection. Gastroenterology 2008;134:1007-1016
19. Chen C, Zhou Y, Zhou Z, et al. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 2004;330:133-142 (Pubitemid 38490426)
20. Gagarin A, Makarenkov V, Zentilli P. Using clustering techniques to improve hit selection in high-throughput screening. J Biomol Screen 2006;11:903-914 (Pubitemid 44847144)
21. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
22. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005;43:1133-1139 (Pubitemid 41584815)
23. Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75:93-109.
24. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzo-pyran-4-one (LY294002). J Biol Chem 1994;269:5241-5248 (Pubitemid 2045363)
25. Hemmings BA. Akt signaling: linking membrane events to life and death decisions. Science 1997;275:628-630 (Pubitemid 27061321)
26. Geltz NR, Augustine JA. The p85 and p110 subunits of phosphatidylinositol 3-kinase-α are substrates, in vitro , for a constitutively associated protein tyrosine kinase in platelets. Blood 1998;91:930-939 (Pubitemid 28078296)
27. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014. (Pubitemid 29449213)
28. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002;8:1957-1963. (Pubitemid 34633759)
29. Itoh N, Semba S, Ito M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127-3134 (Pubitemid 34670495)
30. Chen C, Benjamin MS, Sun X, et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer 2006;118:1346-1355 (Pubitemid 43306519)
31. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 Suppl 4:31-39
32. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-420 (Pubitemid 44142738)
33. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17-23. (Pubitemid 34044674)
34. Levitzki A, Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol Sci 1991;12:171-174
35. Palumbo GA, Yarom N, Gazit A, et al. The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res 1997;57:2434-2439 (Pubitemid 27255903)
36. Burger AM, Kaur G, Alley MC, et al. Tyrphostin AG17, [(3,5-di-tert-butyl- 4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res 1995;55:2794-2799
37. Thyberg J. Tyrphostin A9 and wortmannin perturb the Golgi complex and block proliferation of vascular smooth muscle cells. Eur J Cell Biol 1998;76:33-42. (Pubitemid 28254230)
38. Aizawa K, Suzuki T, Kada N, et al. Regulation of platelet-derived growth factor-A chain by Kruppel-like factor 5: new pathway of cooperative activation with nuclear factor-κB. J Biol Chem 2004;279:70-76 (Pubitemid 38044800)
39. Shindo T, Manabe I, Fukushima Y, et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002;8:856-863 (Pubitemid 34887250)
40. Venkateswarlu S, Dawson DM, St Clair P, et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002;21:78-86. (Pubitemid 34076380)
41. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-385 (Pubitemid 44142736)